Merck & Co., Inc. (MRK) Return on Invested Capital (ROIC): 18.27%
Is Merck & Co., Inc.’s return on invested capital (ROIC) high or low?
Merck & Co., Inc.'s return on invested capital (ROIC) of 18.27% is 43% above its 5-year average of 12.73%, near the high end of its 5-year range (0.71%–18.97%).
The return on invested capital (ROIC) for Merck & Co., Inc. (MRK) is 18.27% as of Wednesday, June 10, 2026. It is below its 12-month average by 1.88% (18.62%).
MRK Return on Invested Capital (ROIC) Chart
MRK Average Return on Invested Capital (ROIC) Chart
MRK Current vs Average Return on Invested Capital (ROIC) Chart
MRK Return on Invested Capital (ROIC) Metrics
RETURN ON INVESTED CAPITAL (ROIC)
18.27%
RETURN ON INVESTED CAPITAL (ROIC) AVG TTM
18.62%
RETURN ON INVESTED CAPITAL (ROIC) AVG 3Y
14.12%
RETURN ON INVESTED CAPITAL (ROIC) AVG 5Y
12.73%
RETURN ON INVESTED CAPITAL (ROIC) AVG 10Y
10.20%
RETURN ON INVESTED CAPITAL (ROIC) AVG 15Y
8.94%
RETURN ON INVESTED CAPITAL (ROIC) AVG 20Y
9.21%
CURRENT VS TTM AVG
-1.88%
CURRENT VS 3Y AVG
+29.39%
CURRENT VS 5Y AVG
+43.46%
CURRENT VS 10Y AVG
+79.07%
CURRENT VS 15Y AVG
+104.29%
CURRENT VS 20Y AVG
+98.39%
MRK Competitors' Return on Invested Capital (ROIC)
| NAME | MARKET CAP | RETURN ON INVESTED CAPITAL (ROIC) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Merck & Co., Inc. (MRK) | — | 18.27% | 18.62% | 14.12% | 12.73% |
| UnitedHealth Group Incorporated (UNH) | $368.44B | 8.23% | 10.28% | 12.20% | 12.63% |
| AbbVie Inc. (ABBV) | $399.54B | 12.97% | 10.91% | 11.35% | 11.16% |
| Amgen Inc. (AMGN) | $183.75B | 13.16% | 11.04% | 11.80% | 12.80% |
| Thermo Fisher Scientific Inc. (TMO) | $179.45B | 7.58% | 7.80% | 8.16% | 9.10% |
| Abbott Laboratories (ABT) | $154.66B | 8.43% | 9.16% | 9.70% | 9.86% |
| Gilead Sciences, Inc. (GILD) | $151.21B | 21.53% | 11.95% | 11.58% | 9.92% |
| Intuitive Surgical, Inc. (ISRG) | $146.44B | 13.71% | 12.85% | 12.25% | 11.92% |
| Pfizer Inc. (PFE) | $146.36B | 8.84% | 9.06% | 10.60% | 10.43% |
| Danaher Corporation (DHR) | $130.25B | 5.72% | 5.90% | 6.54% | 6.70% |
Capital Efficiency
ROIC
18.3%
ROE
19.5%
Merck & Co., Inc. Return on Invested Capital (ROIC) Formula & Definition
ROIC = NOPAT / Invested Capital
Return on invested capital measures the after-tax return a company earns on all capital (debt and equity) invested in the business.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Merck & Co., Inc. Return on Invested Capital (ROIC) FAQ
- What is the return on invested capital (ROIC) for Merck & Co., Inc. (MRK)?
- The return on invested capital (ROIC) for MRK stock is 18.27%.
- Is Merck & Co., Inc.'s return on invested capital (ROIC) high or low?
- Merck & Co., Inc.'s return on invested capital (ROIC) of 18.27% is 43% above its 5-year average of 12.73%, near the high end of its 5-year range (0.71%–18.97%).
- What is the TTM average return on invested capital (ROIC) for Merck & Co., Inc. (MRK)?
- The TTM average return on invested capital (ROIC) for MRK stock is 18.62%.
- What is the 3Y average return on invested capital (ROIC) for Merck & Co., Inc. (MRK)?
- The 3Y average return on invested capital (ROIC) for MRK stock is 14.12%.
- What is the 5Y average return on invested capital (ROIC) for Merck & Co., Inc. (MRK)?
- The 5Y average return on invested capital (ROIC) for MRK stock is 12.73%.
- What is the 10Y average return on invested capital (ROIC) for Merck & Co., Inc. (MRK)?
- The 10Y average return on invested capital (ROIC) for MRK stock is 10.20%.
- What is the 15Y average return on invested capital (ROIC) for Merck & Co., Inc. (MRK)?
- The 15Y average return on invested capital (ROIC) for MRK stock is 8.94%.
- What is the 20Y average return on invested capital (ROIC) for Merck & Co., Inc. (MRK)?
- The 20Y average return on invested capital (ROIC) for MRK stock is 9.21%.
Merck & Co., Inc. Return on Invested Capital (ROIC) History
| DATE | RETURN ON INVESTED CAPITAL (ROIC) |
|---|---|
| 2025-12-31 | 18.27% |
| 2024-12-31 | 18.97% |
| 2023-12-31 | 0.71% |
| 2022-12-31 | 18.53% |
| 2021-12-31 | 13.90% |
| 2020-12-31 | 6.03% |
| 2019-12-31 | 9.42% |
| 2018-12-31 | 9.67% |
| 2017-12-31 | 3.49% |
| 2016-12-31 | 5.91% |
| 2015-12-31 | 7.33% |
| 2014-12-31 | 5.60% |
| 2013-12-31 | 6.77% |
| 2012-12-31 | 7.73% |
| 2011-12-31 | 8.61% |
| 2010-12-31 | 2.15% |
| 2009-12-31 | 3.49% |
| 2008-12-31 | 13.82% |
| 2007-12-31 | 14.40% |
| 2006-12-31 | 7.93% |
| 2005-12-31 | 10.66% |
| 2004-12-31 | 14.91% |
| 2003-12-31 | 19.07% |
| 2002-12-31 | 16.47% |
| 2001-12-31 | 18.00% |
| 2000-12-31 | 18.83% |
| 1999-12-31 | 17.45% |
| 1998-12-31 | 15.58% |
| 1997-12-31 | 19.87% |
| 1996-12-31 | 17.40% |
Related Metrics
About Merck & Co., Inc.
Merck & Co., Inc. is a global healthcare leader with operations spanning two core divisions: Pharmaceuticals and Animal Health. The Pharmaceutical segment is dedicated to human health, offering a broad spectrum of medicinal products. These cover crucial therapeutic areas such as oncology, acute hospital care, immunology, neuroscience, virology, cardiovascular conditions, and diabetes. This division also develops vital preventive vaccines for pediatric, adolescent, and adult populations. Meanwhile, the Animal Health segment focuses on the research, development, manufacturing, and marketing of veterinary medications, vaccines, and comprehensive health management solutions for animals. This division further provides innovative digital products designed for animal identification, traceability, and continuous monitoring. Merck's extensive clientele encompasses drug wholesalers, pharmacies, hospitals, and government agencies. It also serves managed healthcare organizations, including health maintenance organizations (HMOs) and pharmacy benefit managers, as well as various other institutional clients. Additionally, the company supplies products to individual physicians and their distributors, veterinarians, and livestock producers. The organization actively engages in strategic collaborations with companies such as AstraZeneca PLC, Bayer AG, Eisai Co., Ltd., Ridgeback Biotherapeutics, and Gilead Sciences, Inc. These partnerships are specifically aimed at the joint development and commercialization of prolonged-acting therapies for HIV. Established in 1891, Merck & Co., Inc. maintains its corporate headquarters in Kenilworth, New Jersey.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Robert Davis